IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF ILLINOIS
EASTERN DIVISION

DOCMETTO
SEP 2 8 7000

ABBOTT LABORATORIES, an Illinois Corporation, and CENTRAL GLASS COMPANY LTD., a Japanese Corporation Plaintiffs, v. Case HIDGE RONALD GUZMAN BAXTER PHARMACEUTICAL PRODUCTS, INC., MAGISTRATE JUDGE ASHMAN a Delaware Corporation, and BAXTER HEALTHCARE, CORP. a Delaware Corporation Defendants. JURY TRIAL DEMANDED **COMPLAINT**

Abbott Laboratories ("Abbott") and Central Glass Company Ltd. ("Central Glass") by and through their attorneys, hereby complain against the Defendants Baxter Pharmaceutical Products, Inc. and Baxter Healthcare Corp. (collectively "Baxter") as follows.

NATURE OF THE ACTION

1. This is a patent infringement action involving sevoflurane, Abbott's anesthetic inhalant, which it sells under the trademark Ultane®. This anesthetic inhalant is used in the induction and maintenance of general anesthesia in adult and pediatric patients. Abbott filed a New Drug Application and received authorization from the Federal Food and Drug Administration ("FDA") to market and sale sevoflurane in 1995.

THE PARTIES

2. Plaintiff Abbott Laboratories is an Illinois corporation with its principal place of business in Abbott Park, Illinois. Abbott is a diversified health care company.

- 3. Plaintiff Central Glass is a Japanese corporation with its principal place of business in Tokyo, Japan.
- 4. Defendant Baxter Pharmaceutical Products, Inc. is a Delaware corporation with its principal place of business in New Jersey. Baxter Pharmaceutical Products, Inc. is a wholly owned subsidiary of Baxter Healthcare Corp.
- 5. Defendant Baxter Healthcare Corp. is a Delaware corporation with its principal place of business in Deerfield, Illinois.

JURISDICTION AND VENUE

- 6. Jurisdiction is proper under 35 U.S.C. §§ 271(a), (b), and (e) and 281.
- 7. Venue is proper under 28 U.S.C. §§ 1391(b), (c) and (d) and 1400(b).
- 8. This Court has personal jurisdiction over the Defendants because, among other things, Baxter does business and transacts business in this judicial district.

COUNT I –INFRINGEMENT OF UNITED STATES PATENT NO. 5,990,176 (Plaintiffs: Abbott and Central Glass)

- 9. Plaintiffs repeat and reallege the allegations contained in paragraphs 1-8 of their Complaint as if those allegations were set forth verbatim herein.
- 10. On November 23, 1999, the United States Patent and Trademark Office ("PTO") duly and legally issued United States Patent No. 5,990,176 ("the '176 Patent"), entitled "Fluoroether Compositions and Methods For Inhibiting Their Degradation In the Presence of a Lewis Acid". A true and correct copy of the '176 Patent is attached hereto as Exhibit A. Plaintiffs own all rights and interests in the '176 Patent which patent has properly been listed in the FDA Orange Book.

11. Baxter intends to market and sell a sevoflurane product that infringes upon the '176 Patent. Baxter filed with the FDA in Rockville, Maryland an Abbreviated New Drug Application ("ANDA") under 21 U.S.C. § 355(j) to obtain approval for the commercial manufacture, use and sale of sevoflurane. Baxter filed that ANDA to obtain approval to market and sell a generic version of sevoflurane before the expiration date of the '176 Patent. Baxter also filed with the FDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV), a certification alleging that the claims of the '176 Patent are not infringed and are invalid.

12. On or about August 14, 2000, Baxter sent a letter to Abbott and Central Glass by certified mail stating that the sender represented Baxter and was sending the letter on behalf of Baxter to advise Abbott that Baxter had filed an ANDA with respect to sevoflurane and was providing information to Abbott pursuant to 21 U.S.C. § 355(j)(2)(B)(ii). Abbott received this letter on or about August 15, 2000. Central Glass received this letter on or about August 18, 2000.

13. Baxter's sevoflurane product and its method of use for which Baxter seeks FDA approval would infringe one or more claims of the '176 Patent. In addition, under 35 U.S.C. §§ 271(e)(2)(A), Baxter's submission to the FDA of an ANDA and a certification letter pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) to obtain approval for the commercial manufacture, use and sale of sevoflurane before the expiration of the '176 Patent was an act that infringes the claims of the '176 Patent.

WHEREFORE, Plaintiffs pray:

A. That U.S. Patent No. 5,990,176 be judged valid, enforceable, and infringed by Defendants;

- B. That the Court declare this an exceptional case and award Plaintiffs their reasonable costs, expenses, and attorneys' fees pursuant to 35 U.S.C. § 285; and
- C. That the Court award such other and further relief which this Court deems just and proper.

COUNT II -- INFRINGEMENT OF U.S. PATENT NO. 6,074,668 (Plaintiff: Abbott)

- 14. Abbott repeats and realleges the allegations contained in paragraphs 1-8 of the Complaint as if those allegations were set forth verbatim herein.
- 15. On June 13, 2000, the PTO duly and legally issued United States Patent No. 6,074,668 ("the '668 Patent"), entitled "Container For An Inhalation Anesthetic." A true and correct copy of the '668 Patent is attached hereto as Exhibit B. Since its date of issue, Abbott owns all rights, title, and interests in the '668 Patent which patent has been properly listed in the FDA Orange Book.
- 16. Baxter intends to market and sell an inhalation anesthetic product comprising sevoflurane in a manner that would infringe one or more claims of Abbott's '668 Patent. Baxter filed with the FDA in Rockville, Maryland an Abbreviated New Drug Application ("ANDA") under 21 U.S.C. § 355(j) to obtain approval for the commercial manufacture, use and sale of sevoflurane. Baxter filed that ANDA to obtain approval to market and sell a generic version of sevoflurane before the expiration date of the '668 Patent. Baxter also filed with the FDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV), a certification alleging that the claims of the '668 Patent are not infringed and invalid.
- 17. On or about August 14, 2000, Baxter sent a letter to Abbott by certified mail stating that the sender represented Baxter and was sending the letter on behalf of Baxter to advise

Abbott that Baxter had filed an ANDA with respect to sevoflurane and was providing information to Abbott pursuant to 21 U.S.C. § 355(j)(2)(B)(ii). Abbott received this letter on or about August 15, 2000.

18. Baxter's sevoflurane product and its manner and method of use for which Baxter seeks FDA approval would infringe one or more claims of the '668 Patent. In addition, under 35 U.S.C. §§ 271(e)(2)(A), Baxter's submission to the FDA of an ANDA and a certification letter pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) to obtain approval for the commercial manufacture, use and sale of sevoflurane before the expiration of the '668 Patent was an act that infringes the claims of the '668 Patent.

WHEREFORE, Abbott prays:

- A. That U.S. Patent No. 6,074,668 be judged valid, enforceable, and infringed by Defendants;
- B. That the Court declare this an exceptional case and award Abbott its reasonable costs, expenses, and attorneys' fees pursuant to 35 U.S.C. § 285; and
- C. That the Court award such other and further relief which this Court deems just and proper.

JURY DEMAND

Plaintiffs hereby demand trial by jury for all issues triable of right by jury in this action.

Respectfully submitted,

ABBOTT LABORATORIES

CENTRAL-GLASS CO., LTD.

Dated: September 27, 2000 By:

One of Their Attorneys

Edward L. Foote R. Mark McCareins Marie A. Lona Raymond C. Perkins Peggy M. Balesteri Winston & Strawn 35 West Wacker Drive Chicago, Illinois 60601 (312) 558-5600

Sharon E. Jones Abbott Laboratories 100 Abbott Park Road Abbott Park, Illinois 60064 (847) 937-5201

SEE CASE FILE FOR EXHIBITS

Od	136 1.00-07-0030	9 Docume	1111	1 1160 03/21/00 1	age o or ro		
JS 4 (Rev_1/96)	- (SIVIL C	OV	ER SHEET		KOCA	
The JS-44 civil cover sheet at by law, except as provided by of the Clerk of Court for the p	nd the information contain local rules of court. This umose of initiating the civil	ned herein neithe	r replace	nor supplement the filing	and service of pleading nited States in Septembe	s Distriction of the control of the	
I. (a) PLAINTIFFS				DEFENDANTS	UUU	3399	
ABBOTT LABORATORIES				BAXTER PHARM	ACEUTICAL PR	ODUCTS	
CENTRAL GLASS CO., LTD.						ONALD GUZMAN	
					OOD OL IX		
(b) COUNTY OF RESIDENCE OF FIRST LISTED PLAINTIFF				COUNTY OF RESIDENCE OF F	IRST LISTED DEFENDANT	LAKE COUNTY	
(EXCEPT IN U.S. PLAINTIFF CASES)				NOTE: IN LAND COND	EMNATION CASES, USE	THE LOCATION OF THE	
				MACH	DGE ASHMAN		
(C) ATTORNEYS (FIRM NAME, ADDRESS, AND TELEPHONE NUMBER)				ATTORNEYS (IF KNOWN) SEP 2 8 2	oon & s	SEP	
SEE ATTACHMENT) SEL WOL	.00e 4 g	SEP 27	
				ļ		型 自	
II. BASIS OF JURISDI	CTION (PLACE AN "X"	IN ONE BOX ONLY)			ICIPAL PARTIES	ACE AN "X" IN ONE BOX FOR PLAINT	
			or Diversity Cases Only) PT	F DEF	O ONE BOX FOR DEFENDANT)		
3 1 U.S. Government Plaintiff				tizen of This State	ı □ ı Incorporated o of Business	or Principal Place □ 4 □ 4 In This State	
∃ 2 U.S. Government Defendant	☐ 4 Diversity (Indicate Citizens	ship of Parties	C	itizen of Another State 🛛	2 2 Incorporated a	and Principal Place D s D s In Another State	
2 0101.00.01	in Item III)		C	itizen or Subject of a □			
V. ORIGIN		(PLACE AN		Foreign Country ONE BOX ONLY)		Appeal to Distri	
X _{3 1} Original	oved from 👊 s Rema Court Appel		Reinstat Reopen	Transferre		Júdge from	
V. NATURE OF SUIT	(PLACE AN "X" IN ONL		 -	(op sony)			
CONTRACT	TO	RTS		FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES	
] 110 Insurance] 120 Marine	PERSONAL INJURY	PERSONAL INJURY 362 Personal Injury — Med. Malpractice 365 Personal Injury — Product Liability 368 Aspestos Personal Injury Product Liability PERSONAL PROPERTY 370 Cittle Fraud 371 Truth in Lending		S10 Agriculture S20 Other Food & Drug	422 Appeal 28 USC 158	☐ 400 State Reapportionment ☐ 410 Antitrust	
] 130 Miller Act] 140 Negotiable Instrument] 150 Recovery of Overpayment	() 315 Airplane Product Uability 320 Assault, Libel &			G25 Drug Related Selzure of Property 21 USC 881 G30 Uquor Laws G40 R.R. & Truck G50 Airline Regs. G50 Occupational Safety/Health	A23 Withdrawal 28 USC 157	Sanks and Banking	
& Enforcement of Judgment 1 151 Medicare Act	Slander Slander D 330 Federal Employers				PROPERTY RIGHTS		
152 Recovery of Defaulted Student Loans	⊔ability □ 340 Marine				□ 820 Copyrights 翌 830 Patent □ 840 Trademark	☐ 810 Selective Service ☐ 850 Securities/Commodities/	
(Excl. Veterans) 1 153 Recovery of Overpayment	☐ 345 Marine Product Liability			☐ 690 Other		Exchange ### Statement Challenge	
of Veteran's Benefits 3 160 Stockholders' Suits	350 Motor Vehicle 355 Motor Vehicle	280 Other Person Property Dan	mage	LABOR	SOCIAL SECURITY	12 USC 3410 891 Agricultural Acts	
190 Other Contract 195 Contract Product Liability	Product Liability C) 360 Other Personal Injury	385 Property Dan Product Liab		710 Fair Labor Standards Act	☐ \$61 HIA (1395ft) ☐ 862 Black Lung (923) ☐ 863 DIWC/DIWW (405(g))	☐ 892 Economic Stabilization Act ☐ 893 Environmental Matters	
REAL PROPERTY	CIVIL RIGHTS	PRISONER PET	ITIONS	☐ 720 Labor/Mgmt, Relations	☐ 864 SSID Title XVI ☐ 865 RSI (405(g))	☐ 894 Energy Allocation Act ☐ 895 Freedom of Information Act	
210 Land Condemnation 220 Foreclosure	441 Voting 442 Employment	☐ \$10 Motions to Vacate Sentence HABEAS CORPUS:		☐ 730 Labor/Mgmt, Reporting & Disclosure Act ☐ 740 Railway Labor Act	FEDERAL TAX SUITS	900 Appeal of Fee Determinate Under Equal Access to Jus	
230 Rent Lease & Ejectment 240 Tons to Land	Accommodations	☐ 530 General ☐ 535 Death Penal		☐ 790 Other Labor Litigation	☐ 870 Taxes (U.S. Plaintiff	☐ 950 Constitutionality of State Statutes	
245 Ton Product Liability 290 All Other Real Property	444 Welfare 440 Other Civil Rights	540 Mandamus 550 CMI Rights		☐ 791 Empl, Ret. Inc. Security Act	or Defendant)	□ 890 Other Statutory Actions	
1. CAUSE OF ACTIO	ON (CITE THE U.S. CIVIL ST	S\$\$ Prison Con		FILING AND WRITE BRIEF STATEM	26 USC 7609 FNT OF CAUSE		
	DO NOT CITE JURISDIC	CTIONAL STATUTES UN	ILESS DIVE	RSITY.)			
PATENT INFF	RINGEMENT ACT	ION PURSU	TNA	TO 35 U.S.C.	§271		
II. REQUESTED IN CHECK IS THE IS A CLASS ACTION				DEMAND S	CHECK YES	only if demanded in compla	
COMPLAINT CHECK IF THIS IS A CLASS ACTION UNDER FR.C.P. 23				JURY DEM			
'III. This case	is not a refiling of	is not a refiling of a previously dismissed action.					
	•	•		_, previously dismissed b	y Judge	·	
DATE		SIGNATURE O	OF ATTOR	WEY OF RECORD			
9/27/00	ı	\wedge		C. Pullus		/	
11 IMA			W77V.W	> V 19~\ X V \ ₹		4 · / /	

UNITED STATES DISTRICT COURT

ATTACHMENT A TO CIVIL COVER SHEET

(C) Attorneys for Plaintiffs (Firm Name, Address and Telephone Number):

Edward L. Foote R. Mark McCareins Marie A. Lona Raymond C. Perkins Peggy M. Balesteri Winston & Strawn 35 West Wacker Drive Chicago, Illinois 60601 (312) 558-5600

Sharon E. Jones Abbott Laboratories 100 Abbott Park Road Abbott Park, Illinois 60064 (847) 937-5201

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS

In the Matter of:

TRIAL ATTORNEY?

DESIGNATED AS LOCAL COUNSEL?

YES

YES

YES

[]

团

00C 5939 Case Number GE RONALD GUZMAN Judge: MACHSTRATE JUDGE ASHMAN ABBOTT LABORATORIES ET AL BAXTER PHARMACEUTICAL PRODUCTS, INC. ET AL APPEARANCES ARE HEREBY FILED BY THE UNDERSIGNED AS ATTORNEY(S) FOR: 8 ABBOTT LABORATORIES AND CENTRAL GLASS CO., LTD. SEP 2 8 2000 (B) SIGNATURE SIGNATURE NAME NAME Mark McCareins Edward L. Foote FIRM Winston & Strawn Winston & Strawn STREET ADDESS STREET ADDRESS 35 West Wacker Drive 35 West Wacker Drive CITY/STATE/ZIP Chicago, Illinois 60601 Chicago, Illinois 60601 TELEPHONE NUMBER TELEPHONE NUMBER 312-558-5600 312-558-5600 IDENTIFICATION NUMBER (SEE ITEM 4 ON REVERSE) IDENTIFICATION NUMBER (SEE ITEM 4 ON REVERSE) 008446083 MEMBER OF TRIAL BAR? MEMBER OF TRIAL BAR? YES YES NO X 図 TRIAL ATTORNEY? TRIAL ATTORNEY? YES NO X × DESIGNATED AS LOCAL COUNSEL? YES Ю **(C)** (D) SKINATURE SIGNATURE NAME Raymond C. Perkins Marie A. Lona Winston & Strawn Winston & Strawn STREET ADDRESS 35 West Wacker Drive STREET ADDRESS. West Wacker Drive Chicago, IL 60601 CHICago, IL 60601 TELEPHONE NUMBER 312-558-5600 TELEPHONE NUMBER 312-558-5600 identification number (see item 4 on reverse) 6225834 $\begin{array}{l} \hbox{ identification number (see item 4 on reverse)} \\ 6207711 \end{array}$ MEMBER OF TRIAL BAR? MEMBER OF TRIAL BAR? YES NO YES NO 図 X П

TRIAL ATTORNEY?

DESIGNATED AS LOCAL COUNSEL?

図

NO